# OnCo record adult-t-cell-leukaemia-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/adult-t-cell-leukaemia-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "adult-t-cell-leukaemia-lymphoma" ;
  schema:name "Adult T-cell leukaemia/lymphoma"@en ;
  schema:alternateName "ATLL"@en, "ATL"@en, "Adult T-cell leukemia/lymphoma"@en, "Adult T-cell leukaemia"@en, "HTLV-1-associated lymphoma"@en, "Adult T-cell leukaemia/lymphoma (HTLV-1)"@en, "Smouldering ATL"@en, "Chronic ATL"@en, "Acute ATL"@en, "Lymphoma-type ATL"@en ;
  schema:description "A T-cell lymphoma caused by a virus, HTLV-1, which is usually caught in infancy through breast milk and causes the lymphoma decades later in a small minority of the people it infects. It occurs in people from south-western Japan, the Caribbean, west and central Africa, parts of South America, Iran and Romania, and it comes in four forms that are treated very differently."@en ;
  schema:url <https://onco.cc/cancers/adult-t-cell-leukaemia-lymphoma/> ;
  schema:dateModified "2026-09-29"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Adult_T-cell_leukemia/lymphoma> ;
  schema:citation <https://doi.org/10.1038/s41375-022-01620-2>, <https://doi.org/10.1182/blood.2022015851>, <https://doi.org/10.1200/JCO.2008.18.2428>, <https://doi.org/10.1200/JCO.18.00501>, <https://doi.org/10.1111/j.1349-7006.2012.02373.x>, <https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq> ;
  onco:tag "heme", "lymphoma", "subtype-page" ;
  onco:related <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/extranodal-nk-t-cell-lymphoma/>, <https://onco.cc/cancers/t-cell-prolymphocytic-leukaemia/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:drugs <https://onco.cc/drugs/mogamulizumab/>, <https://onco.cc/drugs/interferon-alfa/> ;
  onco:terms <https://onco.cc/terms/lymphoma-htlv-1/>, <https://onco.cc/pathways/oncogenic-viruses/>, <https://onco.cc/terms/lymphoma-classification-2022/>, <https://onco.cc/terms/lymphoma-pit-score/>, <https://onco.cc/terms/lymphoma-b-versus-t-cell/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/> ;
  onco:standardOfCare <https://onco.cc/terms/lymphoma-htlv-1/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/pathways/oncogenic-viruses/>, <https://onco.cc/terms/lymphoma-htlv-1/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/lymphoma-tx-watch-and-wait/>, <https://onco.cc/terms/lymphoma-htlv-1/>, <https://onco.cc/terms/intrathecal-therapy/>, <https://onco.cc/terms/lymphoma-tx-pjp-and-infection-prophylaxis/>, <https://onco.cc/drugs/mogamulizumab/>, <https://onco.cc/drugs/interferon-alfa/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/terms/intrathecal-therapy/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/> .